Short Interest in Equillium, Inc. (NASDAQ:EQ) Increases By 620.6%

Equillium, Inc. (NASDAQ:EQ) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 672,300 shares, a growth of 620.6% from the January 31st total of 93,300 shares. Based on an average daily volume of 771,000 shares, the short-interest ratio is currently 0.9 days. Currently, 3.9% of the shares of the stock are short sold.

Equillium Stock Up 0.2 %

Shares of NASDAQ:EQ traded up $0.00 on Friday, hitting $0.77. 34,616 shares of the company traded hands, compared to its average volume of 1,202,720. The stock has a 50 day simple moving average of $0.74 and a 200-day simple moving average of $0.82. The company has a market cap of $27.10 million, a PE ratio of -5.46 and a beta of 1.79. Equillium has a 52 week low of $0.49 and a 52 week high of $2.99.

Institutional Investors Weigh In On Equillium

A hedge fund recently raised its stake in Equillium stock. DCF Advisers LLC boosted its stake in Equillium, Inc. (NASDAQ:EQ) by 91.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 62,947 shares of the company’s stock after acquiring an additional 29,985 shares during the quarter. DCF Advisers LLC owned 0.18% of Equillium worth $47,000 as of its most recent filing with the SEC. Institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.